Please assess the completion status of the following clinical trial:

Trial Title: PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be a pre-menopausal woman between 18 and 50 years inclusive.~* Have a Body Mass Index (BMI) ≥ 18 and ≤ 40.~* Have FSH levels ≤ 20 mIU/mL~* Have excessive uterine bleeding due to myoma.~* Have regular menstrual cycles~* Have a myomatous uterus \< 16 weeks with at least one myoma ≥ 3 cm in diameter.~* If of childbearing potential the subject must be practicing a non-hormonal method of contraception.~Exclusion Criteria:~* Has a history of or current uterine, cervical, ovarian or breast cancer.~* Has a history of or current endometrium atypical hyperplasia or adenocarcinoma.~* Has a known severe coagulation disorder.~* Has a history of or current treatment for myoma with a Selective Progesterone Receptor Modulator (SPRM).~* Has abnormal hepatic function at study entry.~* Has a positive pregnancy test, is nursing or planning a pregnancy during the course of the study.~* Has a current (within twelve months) problem with alcohol or drug abuse.~* Is currently enrolled in an investigational drug or device study or has participated in such a study within the last 30 days.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Ulipristal acetate (PGL4001) 5mg (Type: EXPERIMENTAL): All subjects will be asked to take a 150mg size tablet (PGL4001 5mg or matching placebo: placebo 5) orally daily for repeated periods 84 days. The first treatment course will start on the first 4 days of menstruation and will be orally administered, once daily (1 tablet of 150mg size), for 84 days. The following three treatment courses should be started in the first two days of a menstrual period.
- Ulipristal acetate (PGL4001) 10mg (Type: EXPERIMENTAL): All subjects will be asked to take a 300mg size tablet (PGL4001 10mg or matching placebo: placebo 10 ) orally daily for repeated periods 84 days. The first treatment course will start on the first 4 days of menstruation and will be orally administered, once daily (1 tablet of 300mg size), for 84 days. The following three treatment courses should be started in the first two days of a menstrual period.

Based on this trial design, predict the completion outcome and termination type (if applicable).